BofA analyst Tal Liani raised the firm’s price target on Cellebrite to $6.75 from $6.15 and keeps a Neutral rating on the shares as the firm adjusted targets for several stocks across its Data Networking and Cybersecurity coverage universe. ARR growth is decelerating, and the company expects ARR growth to converge with subscription growth, while revenue growth is accelerating, notes the firm, which waits for more stable trends given the fluctuations seen in the last few quarters.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CLBT:
- UPDATE – Cellebrite Announces Innovative Case-Closing Technology; Raising the Bar for Modern Investigations
- Cellebrite Announces Innovative Case-Closing Technology; Raising the Bar for Modern Investigations
- Cellebrite Bolsters Digital Intelligence Capabilities for Latin American Nation’s Federal Forces and Expands Investigative Power around Crypto Crime
- Cellebrite and The Exodus Road Provide Digital Intelligence Technology to the National Bureau of Investigations Anti-Human Trafficking Division in the Philippines
- Cellebrite Announces First-Quarter 2023 Results